Agilent Receives FDA Approval for Expanded PD-L1 Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Platform Expansion: Agilent announced FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform, facilitating testing for patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric adenocarcinoma, thereby increasing access to KEYTRUDA® treatment for more patients.
- Workflow Optimization: This approval allows pathology laboratories to consolidate PD-L1 testing across multiple tumor types within a single Dako Omnis workflow, significantly enhancing automation and operational efficiency, which meets the laboratories' demand for standardized testing.
- Multi-Site Study Validation: Agilent conducted a multisite external platform performance comparison study that validated the concordance of PD-L1 IHC 22C3 pharmDx results across different staining platforms, ensuring reliability at appropriate CPS cutoffs, thus boosting confidence in clinical applications.
- Strategic Market Alignment: This expansion aligns with Agilent's strategic goals in the clinical diagnostics field, aiming to provide more convenient testing services that support clinicians in effectively identifying patients eligible for immunotherapy, further solidifying its leadership position in the biomarker testing market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 137.400
Low
160.00
Averages
171.67
High
180.00
Current: 137.400
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilent Receives FDA Approval for Expanded PD-L1 Testing
- Platform Expansion: Agilent announced FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform, facilitating testing for patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric adenocarcinoma, thereby increasing access to KEYTRUDA® treatment for more patients.
- Workflow Optimization: This approval allows pathology laboratories to consolidate PD-L1 testing across multiple tumor types within a single Dako Omnis workflow, significantly enhancing automation and operational efficiency, which meets the laboratories' demand for standardized testing.
- Multi-Site Study Validation: Agilent conducted a multisite external platform performance comparison study that validated the concordance of PD-L1 IHC 22C3 pharmDx results across different staining platforms, ensuring reliability at appropriate CPS cutoffs, thus boosting confidence in clinical applications.
- Strategic Market Alignment: This expansion aligns with Agilent's strategic goals in the clinical diagnostics field, aiming to provide more convenient testing services that support clinicians in effectively identifying patients eligible for immunotherapy, further solidifying its leadership position in the biomarker testing market.
See More
FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use
- Indication Expansion: The FDA has expanded the indication for Agilent's PD-L1 IHC 22C3 pharmDx test to include four new tumor types, such as esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma, enhancing the test's value in cancer treatment decision-making.
- Market Impact: This expansion allows the PD-L1 IHC 22C3 pharmDx test to assist more patients in accessing Merck's Keytruda (pembrolizumab) treatment, which is expected to boost Agilent's competitiveness in the cancer diagnostics market, particularly in the rapidly growing immunotherapy sector.
- Technical Platform: The test is performed on the Dako Omnis platform, integrating advanced detection technology that ensures accuracy and reliability of results, thereby enhancing physician confidence in treatment choices.
- Future Outlook: With the FDA's approval, Agilent is poised to capture a larger market share in the future, potentially attracting more investor interest in its innovative capabilities and market potential within the biotechnology sector.
See More
Agilent Partners with OpenAI and BCG to Accelerate AI Deployment
- Strategic Collaboration: Agilent has partnered with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence across its products, operations, and customer workflows, reflecting the company's ambition and commitment to execution in the AI domain.
- Innovation Drive: By integrating advanced AI capabilities, Agilent aims to enhance the intelligence of its products and services, with plans to significantly improve customer experience and accelerate its new product pipeline over the next six to twelve months.
- Competitive Advantage: This collaboration will enable Agilent to transform AI into a competitive advantage, shifting from pilot projects to scaled deployment, thereby redefining how value is created across the enterprise and enhancing decision-making support.
- Resource Integration: By combining Agilent's scientific expertise with OpenAI's AI research and BCG's large-scale transformation experience, the partnership aims to identify, build, and scale high-impact applied AI solutions, enhancing the overall innovation capacity of the enterprise.
See More
Valuation Analysis of U.S. Healthcare Stocks
- High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
- Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
- Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
- Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
See More
Agilent Technologies Reports Strong Earnings Boosting Stock by 17.25%
- Strong Earnings Report: Agilent Technologies reported $1.83 billion in revenue for Q2 2026, a 10% year-over-year increase, with net income rising 14% to $423 million or $1.49 per share, exceeding analyst expectations and demonstrating robust market performance.
- Growth Across Segments: All three reporting units experienced revenue growth, led by the Applied Markets Group with a 14% increase to $344 million, followed by the life sciences and diagnostics segment with a 12% boost to $732 million, and Agilent CrossLab's revenue rising 6% to $759 million, reflecting the overall health of the company's operations.
- Upgraded Full-Year Guidance: Supported by strong performance, Agilent's management raised its full-year 2026 revenue guidance to $7.39 billion to $7.49 billion, while also increasing its adjusted net income projection to $6 to $6.10 per share, indicating confidence in future earnings.
- Positive Market Reaction: Investors reacted positively to the earnings report, driving Agilent's stock price up by 17.25% during the trading session, thereby enhancing the company's market capitalization and solidifying its position in the medical device and healthcare technology sectors.
See More
Agilent Technologies Exceeds Quarterly Earnings Expectations
- Significant Performance Growth: Agilent Technologies reported $1.83 billion in revenue for Q2 2026, marking a 10% year-over-year increase and surpassing analyst expectations of $1.8 billion, demonstrating the company's robust performance in the medical device and healthcare tech sectors.
- Net Income Increase: The company's non-GAAP net income reached $423 million, a 14% increase from the previous year, with earnings per share at $1.49, reflecting a sustained enhancement in profitability.
- Growth Across Business Units: All three of Agilent's reporting units saw revenue growth, with the Applied Markets Group rising 14% to $344 million and the Life Sciences and Diagnostics segment increasing 12% to $732 million, showcasing the resilience of the company's diversified business.
- Upward Revision of Annual Guidance: Management raised the lower end of its 2026 revenue guidance to $7.39 billion to $7.49 billion, while also adjusting the non-GAAP net income projection to $6 to $6.10 per share, indicating strong confidence in future performance.
See More
Agilent Receives FDA Approval for Expanded PD-L1 Testing
- Platform Expansion: Agilent announced FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform, facilitating testing for patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric adenocarcinoma, thereby increasing access to KEYTRUDA® treatment for more patients.
- Workflow Optimization: This approval allows pathology laboratories to consolidate PD-L1 testing across multiple tumor types within a single Dako Omnis workflow, significantly enhancing automation and operational efficiency, which meets the laboratories' demand for standardized testing.
- Multi-Site Study Validation: Agilent conducted a multisite external platform performance comparison study that validated the concordance of PD-L1 IHC 22C3 pharmDx results across different staining platforms, ensuring reliability at appropriate CPS cutoffs, thus boosting confidence in clinical applications.
- Strategic Market Alignment: This expansion aligns with Agilent's strategic goals in the clinical diagnostics field, aiming to provide more convenient testing services that support clinicians in effectively identifying patients eligible for immunotherapy, further solidifying its leadership position in the biomarker testing market.
See More
FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use
- Indication Expansion: The FDA has expanded the indication for Agilent's PD-L1 IHC 22C3 pharmDx test to include four new tumor types, such as esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma, enhancing the test's value in cancer treatment decision-making.
- Market Impact: This expansion allows the PD-L1 IHC 22C3 pharmDx test to assist more patients in accessing Merck's Keytruda (pembrolizumab) treatment, which is expected to boost Agilent's competitiveness in the cancer diagnostics market, particularly in the rapidly growing immunotherapy sector.
- Technical Platform: The test is performed on the Dako Omnis platform, integrating advanced detection technology that ensures accuracy and reliability of results, thereby enhancing physician confidence in treatment choices.
- Future Outlook: With the FDA's approval, Agilent is poised to capture a larger market share in the future, potentially attracting more investor interest in its innovative capabilities and market potential within the biotechnology sector.
See More
Agilent Partners with OpenAI and BCG to Accelerate AI Deployment
- Strategic Collaboration: Agilent has partnered with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence across its products, operations, and customer workflows, reflecting the company's ambition and commitment to execution in the AI domain.
- Innovation Drive: By integrating advanced AI capabilities, Agilent aims to enhance the intelligence of its products and services, with plans to significantly improve customer experience and accelerate its new product pipeline over the next six to twelve months.
- Competitive Advantage: This collaboration will enable Agilent to transform AI into a competitive advantage, shifting from pilot projects to scaled deployment, thereby redefining how value is created across the enterprise and enhancing decision-making support.
- Resource Integration: By combining Agilent's scientific expertise with OpenAI's AI research and BCG's large-scale transformation experience, the partnership aims to identify, build, and scale high-impact applied AI solutions, enhancing the overall innovation capacity of the enterprise.
See More
Valuation Analysis of U.S. Healthcare Stocks
- High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
- Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
- Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
- Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
See More
Agilent Technologies Reports Strong Earnings Boosting Stock by 17.25%
- Strong Earnings Report: Agilent Technologies reported $1.83 billion in revenue for Q2 2026, a 10% year-over-year increase, with net income rising 14% to $423 million or $1.49 per share, exceeding analyst expectations and demonstrating robust market performance.
- Growth Across Segments: All three reporting units experienced revenue growth, led by the Applied Markets Group with a 14% increase to $344 million, followed by the life sciences and diagnostics segment with a 12% boost to $732 million, and Agilent CrossLab's revenue rising 6% to $759 million, reflecting the overall health of the company's operations.
- Upgraded Full-Year Guidance: Supported by strong performance, Agilent's management raised its full-year 2026 revenue guidance to $7.39 billion to $7.49 billion, while also increasing its adjusted net income projection to $6 to $6.10 per share, indicating confidence in future earnings.
- Positive Market Reaction: Investors reacted positively to the earnings report, driving Agilent's stock price up by 17.25% during the trading session, thereby enhancing the company's market capitalization and solidifying its position in the medical device and healthcare technology sectors.
See More
Agilent Technologies Exceeds Quarterly Earnings Expectations
- Significant Performance Growth: Agilent Technologies reported $1.83 billion in revenue for Q2 2026, marking a 10% year-over-year increase and surpassing analyst expectations of $1.8 billion, demonstrating the company's robust performance in the medical device and healthcare tech sectors.
- Net Income Increase: The company's non-GAAP net income reached $423 million, a 14% increase from the previous year, with earnings per share at $1.49, reflecting a sustained enhancement in profitability.
- Growth Across Business Units: All three of Agilent's reporting units saw revenue growth, with the Applied Markets Group rising 14% to $344 million and the Life Sciences and Diagnostics segment increasing 12% to $732 million, showcasing the resilience of the company's diversified business.
- Upward Revision of Annual Guidance: Management raised the lower end of its 2026 revenue guidance to $7.39 billion to $7.49 billion, while also adjusting the non-GAAP net income projection to $6 to $6.10 per share, indicating strong confidence in future performance.
See More
